EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026 - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026 ##### Up next ###### [WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy](https://thailandbusinessnews.net/press-release/wuxi-biologics-receives-brazil-anvisa-gmp-certification-to-enable-global-commercial-manufacturing-of-innovative-cancer-immunotherapy/) Published on 30 June 2026 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) SAN DIEGO, June 30, 2026 /PRNewswire/ — At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market opportunities through business matchmaking and global partnership discussions. While antibody-drug conjugates, other oncology and immunology biologics, and biosimilars continue to drive growth, CDMOs are gaining strategic importance amid ongoing global supply chain restructuring. [![EirGenix showcases its complete HER2-positive breast cancer biosimilar product portfolio and one-stop integrated CDMO platform at BIO 2026. Image: GeneOnline](https://mmx.prnasia.com/media/MS1875304/2cb2c4cc897644b2b60661fad5405a76.jpg?id=OA2744860&p=medium600 "EirGenix showcases its complete HER2-positive breast cancer biosimilar product portfolio and one-stop integrated CDMO platform at BIO 2026. Image: GeneOnline")](https://mmx.prnasia.com/media/MS1875304/2cb2c4cc897644b2b60661fad5405a76.jpg?id=OA2744860&p=medium600) EirGenix showcases its complete HER2-positive breast cancer biosimilar product portfolio and one-stop integrated CDMO platform at BIO 2026. Image: GeneOnline In an industry shifting from single-product competition toward platform-based and combination-therapy strategies amid geopolitical uncertainty, [EirGenix](https://www.eirgenix.com/) addresses the challenge of finding new growth engines in mature markets through its dual-track approach. By combining targeted biosimilar development with a flexible CDMO model, the company captures high-potential oncology opportunities while helping partners accelerate global commercialization. **Breast Cancer Remains a Core Battlefield in Oncology Innovation** According to the World Health Organization (WHO), approximately 2.3 million women were diagnosed with breast cancer in 2022, making it the second most commonly diagnosed cancer worldwide. The large patient population and steadily rising treatment demand continue to drive sustained pharmaceutical investment in the field. Market research from Grand View Research projects that the global breast cancer drug market will expand from USD 36.6 billion in 2024 to USD 69.7 billion by 2033, representing a compound annual growth rate (CAGR) of 7.1%. HER2-positive breast cancer accounts for approximately 15% to 20% of all breast cancer cases. Historically, this subtype was associated with aggressive tumor biology and poor prognosis. However, the introduction of trastuzumab validated HER2 as a therapeutic target and reshaped the treatment paradigm. Since then, innovation in HER2-positive therapy has accelerated. Dual-target regimens, subcutaneous formulations, and antibody-drug conjugate (ADC)-based approaches have reshaped the competitive landscape. Today, differentiation extends beyond efficacy, increasingly focusing on treatment convenience and patient experience. **Biosimilars for HER2-Positive Breast Cancer Drive EirGenix’s Next Growth Phase** The global biopharmaceutical industry is entering a major patent cliff, as approximately $300 billion of biologics are expected to lose patent protection over the next decade. This transition is creating significant opportunities for biosimilar developers across major therapeutic areas, especially in oncology and immunology. This is unlocking a vast market potential for biosimilars. While [118](https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void-in-the-us) biologics are set to lose exclusivity by 2034, a striking 106 of them currently have no biosimilars in development. At the same time, global regulatory frameworks are becoming increasingly harmonized. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are aligning expectations for biosimilar approval pathways. Development requirements are increasingly focused on in vitro comparability and on pharmacokinetic bioequivalence data, reflecting a more streamlined regulatory approach. This shift is reducing reliance on large-scale Phase III clinical trials, ultimately shortening development timelines while lowering costs and clinical risk. Against this backdrop, EirGenix has strategically prioritized HER2-positive breast cancer within its biosimilar portfolio. The company’s pipeline spans multiple modalities, including trastuzumab and pertuzumab, as well as subcutaneous combination formulations designed to improve treatment convenience and administration efficiency. In parallel, EirGenix is advancing development efforts in next-generation ADC biosimilars. Beyond single-agent development, EirGenix is also exploring combination therapy strategies to address mechanisms of resistance in oncology treatment. These include potential co-development approaches involving ADC biosimilars alongside immune checkpoint inhibitors such as atezolizumab, as well as other targeted therapies including daratumumab. As additional oncology biologics approach patent expiration, the company continues to evaluate and prioritize future targets across its development pipeline. This proactive portfolio strategy is designed to strengthen its positioning in the rapidly evolving immuno-oncology biosimilar landscape. **Supply Chain Restructuring Elevates the Strategic Role of CDMO Partners** Beyond biosimilars, [CDMO](https://www.geneonline.com/eirgenix-portialin-interview-utm_sourcegoogleutm_mediumpost_0611utm_campaigneirgenix/) services represent a second core pillar of EirGenix’s business strategy. Global supply chain restructuring, the rapid rise of biotech startups, and increasing demand for biologics are reshaping outsourcing models across the pharmaceutical industry. In the United States, companies of all sizes are increasingly relying on external partners to support both development and manufacturing activities. This shift is driven by the need to reduce capital expenditure while improving R&D efficiency and operational flexibility. With demonstrated leadership in commercial-scale GMP biologics manufacturing, EirGenix provides integrated CDMO services across the full product lifecycle. Unlike development-focused CDMOs with limited scale and late-stage capabilities, EirGenix operates a fully integrated, commercially scaled platform spanning cell line engineering, process and analytical development, technology transfer, and GMP manufacturing. This delivers strong performance across the entire value chain from early-stage development through commercialization. Its service scope covers monoclonal antibodies, bispecific antibodies (BsAbs), and other complex biologics. By integrating these capabilities, EirGenix expands cross-border collaboration opportunities and reinforces its positioning in the global biologics outsourcing market. **EirGenix Advances Dual-Track Growth in Biosimilars and CDMO Services at BIO Convention** The United States remains the largest pharmaceutical market globally. At BIO 2026, EirGenix strengthened its international visibility by showcasing its R&D capabilities and engaging in active partnering discussions and industry networking. The company reiterated its commitment to expanding its global footprint, with a strategic focus on capturing opportunities from biosimilar patent expirations and increasing global demand for CDMO partnerships. EirGenix highlighted its long-term dual-track growth strategy: advancing high-value biosimilar assets while leveraging its commercial-scale development and manufacturing platform to support global clients across the entire product lifecycle. This integrated approach is designed to accelerate development timelines for partners while improving commercialization efficiency. Ultimately, it positions EirGenix as an integrated enabler within the rapidly growing global biologics ecosystem. **Contact:** Press GeneOnline +886-225140360 [Source link ](http://www.prnasia.com/story/archive/4995098_HK95098_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/z-com-launches-new-platform-at-computex-2026/) ![Z-COM Launches NEW Platform at Computex 2026](https://i0.wp.com/mma.prnasia.com/media2/2991637/2026_Comutex_PR_hero_visual.jpg?resize=260%2C140&ssl=1 "Z-COM Launches NEW Platform at Computex 2026") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Z-COM Launches NEW Platform at Computex 2026 An Edge-Native Infrastructure Platform Integrating Network Control, AI Operations, and Energy ManagementOne… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - June 1, 2026 [](https://thailandbusinessnews.net/press-release/arduino-and-qualcomm-launch-hacksters-first-developer-contest-of-2026-global-competition-kicks-off-with-300-arduino-uno-q-boards-and-opportunities-to-showcase-edge-ai-innovation/) ## Arduino and Qualcomm Launch Hackster's First Developer Contest of 2026 Global Competition Kicks Off With 300 Arduino UNO Q Boards and Opportunities to Showcase Edge AI Innovation SAN DIEGO, March 3, 2026 /PRNewswire/ — Arduino and Qualcomm Technologies, Inc. have… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - March 4, 2026 [](https://thailandbusinessnews.net/press-release/nippon-budokan-to-showcase-japanese-martial-arts-in-singapore-for-republics-60th-independence-anniversary/) ## Nippon Budokan to Showcase Japanese Martial Arts in Singapore for Republic's 60th Independence Anniversary SINGAPORE, Oct. 13, 2025 /PRNewswire/ — To mark the 60th anniversary of… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - October 13, 2025 ##### Most Read - [![S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/s2s-china-announces-2026-finalists-ten-standout-teams-set-to-pitch-global-investors-at-westlake-university/ "S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University") [S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University](https://thailandbusinessnews.net/press-release/s2s-china-announces-2026-finalists-ten-standout-teams-set-to-pitch-global-investors-at-westlake-university/ "S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University") - [![Insta360 Opens First Flagship Store Outside Asia In New York's Times Square Amid Global Retail Expansion](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/insta360-opens-first-flagship-store-outside-asia-in-new-yorks-times-square-amid-global-retail-expansion/ "Insta360 Opens First Flagship Store Outside Asia In New York's Times Square Amid Global Retail Expansion") [Insta360 Opens First Flagship Store Outside Asia In New York's Times Square Amid Global Retail Expansion](https://thailandbusinessnews.net/press-release/insta360-opens-first-flagship-store-outside-asia-in-new-yorks-times-square-amid-global-retail-expansion/ "Insta360 Opens First Flagship Store Outside Asia In New York's Times Square Amid Global Retail Expansion") - [![Global Online Debut for AISpeech's New Products For Education and Conferencing](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/global-online-debut-for-aispeechs-new-products-for-education-and-conferencing/ "Global Online Debut for AISpeech's New Products For Education and Conferencing") [Global Online Debut for AISpeech's New Products For Education and Conferencing](https://thailandbusinessnews.net/press-release/global-online-debut-for-aispeechs-new-products-for-education-and-conferencing/ "Global Online Debut for AISpeech's New Products For Education and Conferencing") - [![ID Quantique's Clavis XG: The World's First Quantum Key Distribution (QKD) Product to Obtain National Security Certification](https://i0.wp.com/r2.thailandbusinessnews.net/2025/01/ID_Quantique_Clavis_XG.jpg?fit=599%2C337&ssl=1&resize=40%2C40)](https://thailandbusinessnews.net/press-release/id-quantiques-clavis-xg-the-worlds-first-quantum-key-distribution-qkd-product-to-obtain-national-security-certification/ "ID Quantique's Clavis XG: The World's First Quantum Key Distribution (QKD) Product to Obtain National Security Certification") [ID Quantique's Clavis XG: The World's First Quantum Key Distribution (QKD) Product to Obtain National Security Certification](https://thailandbusinessnews.net/press-release/id-quantiques-clavis-xg-the-worlds-first-quantum-key-distribution-qkd-product-to-obtain-national-security-certification/ "ID Quantique's Clavis XG: The World's First Quantum Key Distribution (QKD) Product to Obtain National Security Certification") - [![DXC Ranked Top Individual Life Insurance Core Technology Provider by Everest Group](https://i0.wp.com/r2.thailandbusinessnews.net/2025/04/DXC_Technology_Company_DXC_Ranked_Top_Individual_Life_Insurance.jpg?fit=599%2C359&ssl=1&resize=40%2C40)](https://thailandbusinessnews.net/press-release/dxc-ranked-top-individual-life-insurance-core-technology-provider-by-everest-group/ "DXC Ranked Top Individual Life Insurance Core Technology Provider by Everest Group") [DXC Ranked Top Individual Life Insurance Core Technology Provider by Everest Group](https://thailandbusinessnews.net/press-release/dxc-ranked-top-individual-life-insurance-core-technology-provider-by-everest-group/ "DXC Ranked Top Individual Life Insurance Core Technology Provider by Everest Group") - [![Qatar Foundation - Wilton Park Dialogue Calls for Global Action to Drive Social Development Through Sport](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/qatar-foundation-wilton-park-dialogue-calls-for-global-action-to-drive-social-development-through-sport/ "Qatar Foundation - Wilton Park Dialogue Calls for Global Action to Drive Social Development Through Sport") [Qatar Foundation - Wilton Park Dialogue Calls for Global Action to Drive Social Development Through Sport](https://thailandbusinessnews.net/press-release/qatar-foundation-wilton-park-dialogue-calls-for-global-action-to-drive-social-development-through-sport/ "Qatar Foundation - Wilton Park Dialogue Calls for Global Action to Drive Social Development Through Sport") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/global-times-how-mohe-chinas-northernmost-and-coldest-city-turns-ice-and-snow-into-invaluable-assets/) ## Global Times: How Mohe, China's northernmost and coldest city, turns ice and snow into invaluable assets BEIJING, Sept. 20, 2026 /PRNewswire/ — At 53 degrees north latitude, Mohe… [](https://thailandbusinessnews.net/press-release/jacc-clinical-electrophysiology-publishes-12-month-outcomes-from-field-medicals-first-in-human-field-pulse-trial-94-2-per-vein-pvi-durability-with-optimized-waveform/) ![JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform](https://i0.wp.com/mmx.prnasia.com/media/MS1690629/Field-Medical-FieldForce-Ablation-System-Next-generation-PFA.jpg?resize=260%2C140&ssl=1 "JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform") ## JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform Late-breaking HRX data advance Field Medical’s "instantaneous ablation"… [](https://thailandbusinessnews.net/press-release/gamesir-announces-official-fortnite-mobile-controller-collection/) ![GameSir Announces Official Fortnite Mobile Controller Collection](https://i0.wp.com/mmx.prnasia.com/media/MS1992163/20260920063028EDT_image_1.jpg?resize=260%2C140&ssl=1 "GameSir Announces Official Fortnite Mobile Controller Collection") ## GameSir Announces Official Fortnite Mobile Controller Collection Officially Licensed Fortnite Edition Mobile Controllers Deliver Console-Level Precision… [](https://thailandbusinessnews.net/press-release/pinglu-canal-connects-rivers-sea-and-new-opportunities/) ## Pinglu Canal connects rivers, sea, and new opportunities BEIJING, Sept. 20, 2026 /PRNewswire/ — A report from People’s Daily The…